We have located links that may give you full text access.
Aripiprazole versus quetiapine in treatment-resistant obsessive-compulsive disorder: a double-blind clinical trial.
Therapeutic Advances in Psychopharmacology 2015 Februrary
INTRODUCTION: Around 40-60% of the patients with obsessive-compulsive disorder (OCD) remain unimproved by serotonin reuptake inhibitors (SRIs). Goal of this study was to compare the efficiency and safety of aripiprazole versus quetiapine, in patients with OCD, who did not respond effectively to fluvoxamine.
METHOD: A total of 44 female inpatients with OCD, who did not respond successfully to fluvoxamine at maximum dose (300 mg/day) and duration (12 weeks), were assigned randomly, in a double-blind trial, to receive aripiprazole (n = 22) or quetiapine (n = 22), in addition to their SRI, for 12 weeks. Treatment response was assessed by the Yale-Brown Obsessive-Compulsive Scale (YBOCS), as primary outcome measure, and Clinical Global Impressions-Severity Scale (CGI-S), as a secondary outcome measure.
RESULTS: A total of 27.27% of the cases in the aripiprazole group (n = 6) and 54.54% of them in the quetiapine cluster (n = 12) responded moderately to the aforesaid augmentation. The mean ± SD baseline YBOCS score of 33.27 ± 3.90 dropped to a mean of 30.72 ± 4.67 (p = 0.06) in the aripiprazole group, and from 31.18 ± 4.93 to 27.97 ± 3.71 (p = 0.01) in the quetiapine group, at the end of the evaluation. There was no significant change with respect to CGI-S in either of the aforesaid groups.
CONCLUSION: This study shows that treatment-resistant OCD patients may benefit more from addition of quetiapine in comparison with aripiprazole, to their ongoing SRI therapy.
METHOD: A total of 44 female inpatients with OCD, who did not respond successfully to fluvoxamine at maximum dose (300 mg/day) and duration (12 weeks), were assigned randomly, in a double-blind trial, to receive aripiprazole (n = 22) or quetiapine (n = 22), in addition to their SRI, for 12 weeks. Treatment response was assessed by the Yale-Brown Obsessive-Compulsive Scale (YBOCS), as primary outcome measure, and Clinical Global Impressions-Severity Scale (CGI-S), as a secondary outcome measure.
RESULTS: A total of 27.27% of the cases in the aripiprazole group (n = 6) and 54.54% of them in the quetiapine cluster (n = 12) responded moderately to the aforesaid augmentation. The mean ± SD baseline YBOCS score of 33.27 ± 3.90 dropped to a mean of 30.72 ± 4.67 (p = 0.06) in the aripiprazole group, and from 31.18 ± 4.93 to 27.97 ± 3.71 (p = 0.01) in the quetiapine group, at the end of the evaluation. There was no significant change with respect to CGI-S in either of the aforesaid groups.
CONCLUSION: This study shows that treatment-resistant OCD patients may benefit more from addition of quetiapine in comparison with aripiprazole, to their ongoing SRI therapy.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app